[慢性病和SGLT2抑制剂:单中心经验]
Federica Spaltini1, Elvira Mancini1, Patrizia Vio1
1SOC Nefrologia e dialisi, Ospedale Castelli, Verbania.
概括
这项研究探讨了Dapagliflozin在慢性病患者的有效性和安全性. 结果表明,它有可能成为减缓病进展的新治疗方案.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 慢性病 (CKD) 很普遍,经常被诊断不足,是心血管事件和死亡率的重要危险因素.
- ангиотензин转化酶 (ACE) 抑制剂和 ангиотензин受体阻断剂 (ARB) 是CKD的主要治疗方法.
- -葡萄糖共运输体2 (SGLT2) 抑制剂代表了对脏疾病的新疗法.
研究的目的:
- 评估Dapagliflozin在病患者群体中的疗效和安全性.
- 评估Dapagliflozin在控制慢性病进展中的作用.
主要方法:
- 一个单一中心的观测研究,从2023年2月到2024年6月进行.
- 招募了21名糖尿病和7名非糖尿病的CKD患者,他们接受了最大的氨酸-血管新生素系统阻塞.
- 每月进行血液检查和尿液培养 (根据需要) 收集.
主要成果:
- 该研究评估了Dapagliflozin在患有慢性病的患者中的疗效和安全性.
- 收集了有关患者结局和潜在副作用的数据.
结论:
- 达帕格利弗洛辛 (Dapagliflozin) 是慢性病患者的治疗选择.
- 进一步的研究可能会证实它在减缓疾病进展和改善心血管结果方面的作用.
相关概念视频
Chronic Kidney Disease III: Interprofessional Care
82
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
82
Chronic Kidney Disease I: Introduction
76
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
76
Chronic Kidney Disease II: Clinical Manifestations
104
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
104
Acute Kidney Injury IV: Diagnostic Studies and Prevention
59
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
59
Acute Kidney Injury III: Clinical Manifestations
97
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
97
Kidney Transplant II: Surgical Procedure
78
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
78


